JTCS Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sarris, G. E.
Right arrow Articles by Miller, D. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sarris, G. E.
Right arrow Articles by Miller, D. C.

The Journal of Thoracic and Cardiovascular Surgery, Vol 97, 841-854, Copyright © 1989 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association


ARTICLES

Inhibition of accelerated cardiac allograft arteriosclerosis by fish oil

GE Sarris, RS Mitchell, ME Billingham, JR Glasson, PD Cahill and DC Miller
Department of Cardiovascular Surgery, Stanford University School of Medicine, Calif.

Accelerated coronary arteriosclerosis remains the most important factor limiting long-term survival of heart transplant recipients, and dietary fish oil supplementation with omega-3 polyunsaturated fatty acids has been suggested to have a protective effect against coronary disease in epidemiologic studies and to inhibit arteriosclerosis in animal experiments. Therefore we tested the hypothesis that fish oil administration inhibits the development of allograft coronary arteriosclerosis by using a heterotopic heart transplant model. Three groups of Lewis rats (n = 10 each) received heterotopic heart transplants from Brown-Norway donors and were treated with cyclosporine intraperitoneally on a tapering schedule. Group 1 received fish oil daily by gavage (2 ml/kg/day; Emulsified Super MaxEpa, Twin Labs, Ronkonkona, N.Y.). Group 2 received an equal amount of safflower oil, as well as aspirin (1 mg/kg/day) and dipyridamole (3 mg/kg/day). Group 3 received safflower oil only. All rats were put to death 110 days later, at which time there was no statistically significant difference in graft function as assessed by palpation (scale 0 to 4, mean = 3.7 +/- 0.5 [+/- standard deviation]; analysis of variance: p = 0.72) or in microscopic grade of rejection (scale, 0 = none to 3 = severe, mean 2.1 +/- 0.6; analysis of variance: p = 0.68) between any of the groups. The coronary arteries were histologically scored for the degree of arteriosclerosis (scale, 0 = normal to 3 = occluded), and a mean grade of coronary disease was calculated for each heart. The fish oil-treated group had significantly less severe allograft coronary arteriosclerosis (analysis of variance: p = 0.005) than did groups 2 and 3 (mean grade 0.23 +/- 0.22 versus 1.04 +/- 0.75 and 0.96 +/- 0.55 (p less than 0.05, Scheffe F test), whereas groups 2 and 3 had similar degrees of coronary disease (p = no significant difference). These data demonstrate that fish oil supplementation inhibited accelerated coronary arteriosclerosis in this cyclosporine-treated heart allograft rat model, whereas antiplatelet agents in these doses were ineffective. Although the mechanism of this protective effect remains incompletely understood, it does not appear to involve enhanced immunosuppression. Fish oil and specific omega-3 polyunsaturated fatty acids should be further investigated as potentially useful agents to ameliorate accelerated allograft coronary arteriosclerosis in other animal species and perhaps eventually in man.


This article has been cited by other articles:


Home page
J. Immunol.Home page
B. Metzler, P. Gfeller, M. Bigaud, J. Li, G. Wieczorek, C. Heusser, P. Lake, and A. Katopodis
Combinations of Anti-LFA-1, Everolimus, Anti-CD40 Ligand, and Allogeneic Bone Marrow Induce Central Transplantation Tolerance through Hemopoietic Chimerism, Including Protection from Chronic Heart Allograft Rejection
J. Immunol., December 1, 2004; 173(11): 7025 - 7036.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
C. von Schacky
n-3 Fatty acids and the prevention of coronary atherosclerosis1
Am. J. Clinical Nutrition, January 1, 2000; 71(1): 224S - 227S.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
H. Holschermann, R. M. Bohle, H. Zeller, H. Schmidt, U. Stahl, L. Fink, H. Grimm, H. Tillmanns, and W. Haberbosch
In Situ Detection of Tissue Factor within the Coronary Intima in Rat Cardiac Allograft Vasculopathy
Am. J. Pathol., January 1, 1999; 154(1): 211 - 220.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J.-i. Suzuki, M. Isobe, M. Aikawa, M. Kawauchi, I. Shiojima, N. Kobayashi, A. Tojo, T. Suzuki, K. Kimura, T. Nishikawa, et al.
Nonmuscle and Smooth Muscle Myosin Heavy Chain Expression in Rejected Cardiac Allografts: A Study in Rat and Monkey Models
Circulation, September 1, 1996; 94(5): 1118 - 1124.
[Abstract] [Full Text]


Home page
CirculationHome page
T. Hirozane, A. Matsumori, Y. Furukawa, and S. Sasayama
Experimental Graft Coronary Artery Disease in a Murine Heterotopic Cardiac Transplant Model
Circulation, January 15, 1995; 91(2): 386 - 392.
[Abstract] [Full Text]


Home page
PERSPECT VASC SURG ENDOVASC THERHome page
L. K. Birinyi and F. W. Logerfo
Intimal Hyperplasia: Evolving Concepts of Pathophysiology and Therapy
Perspectives in Vascular Surgery and Endovascular Therapy, January 1, 1989; 2(2): 97 - 111.
[PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1989 by The American Association for Thoracic Surgery.